Consensus on medical treatment of non-small-cell lung cancer—update 2004

Zielinski, Christoph; Beinert, T.; Crawford, Jeffrey; Fischer, Jürgen R.; Georgoulias, Vassilis; Gridelli, Cesare; Hirsch, Fred R.; Jassem, Jacek; Herold, C.; Kosmidis, P.; Krainer, Michael; Krzakowski, Maciej; Manegold, C.; Pirker, Robert; Pujol, Jean-Louis; Thatcher, Nick; Tomek, Sandra; Zandwijk, Nico van; Zöchbauer‐Müller, Sabine; Zwitter, Matjaž

doi:10.1016/j.lungcan.2005.05.014

Cited by 3 publications

(1 citation statement)

References 64 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are associated only with cisplatin-based chemotherapy regardless of the regimen type. Chemotherapy also constitutes a valuable therapeutic approach in palliative patients above 70 years of age with good performance status without concomitant severe diseases [7,8], but its efficacy in patients with poor performance status remains controversial [9,10,11]. Current recommendations of the Polish Group of Lung Cancer do not recommend treatment longer than 4 cycles of chemotherapy in patients with an objective response [12,13,14].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer

Kowalski

Krzakowski²,

Jaśkiewicz³

et al. 2012

Respiration

View full text Add to dashboard Cite

Background: Chemotherapy is the principal treatment method for patients with advanced non-small-cell lung cancer (NSCLC). Treatment with platinum-based and novel chemotherapeutic regimens, compared to monotherapy, slightly increases the response rates to 20-40%. The predictive and prognostic values of molecular factors are highly variable; however, data on clinical-demographic factors are still burdened by significant limitations. Objectives: The aim of this study was to assess the prognostic value of synaptophysin and chromogranin A protein expression in patients receiving palliative chemotherapy for advanced NSCLC. Methods: The study population consisted of 23 women and 116 men. The median age was 57.3 years. Expression of synaptophysin and chromogranin was assessed using a two-step model of immunohistochemical staining. Level 0 represented lack of activity, while level 1 represented its expression. Results: Expression of synaptophysin and chromogranin A was observed in 12 (8.6%) and 5 (3.6%) patients, respectively. The risk of death was significantly lower in patients with expression of synaptophysin (p = 0.008) and chromogranin A (p = 0.014). The 12- and 24-month survival rate of patients with synaptophysin expression was 64% (95% CI 0.35-0.93), while for patients without expression it was 46% (95% CI 0.36-0.56) and 16% (95% CI 0.07-0.25), respectively. The 12- and 24-month survival rate of patients with chromogranin expression was 80% (95% CI 0.44-1.00), while for chromogranin A-negative patients it was 47% (95% CI 0.37-0.57) and 19% (95% CI 0.10-0.28), respectively. We did not observe associations between expression of synaptophysin and chromogranin A and the other typical prognostic factors. Conclusions: Expression of synaptophysin and chromogranin A was associated with a longer median overall survival and might have prognostic value. These results should be confirmed in a prospective study.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer

Kowalski

Krzakowski²,

Jaśkiewicz³

et al. 2012

Respiration

View full text Add to dashboard Cite

show abstract

memo – New official Journal of CECOG

Zielinski¹

2008

memo

View full text Add to dashboard Cite

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer

et al. 2012

View full text Add to dashboard Cite

The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG), which has published such consensus statements in the years 2002 and 2005 (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer--update 2004. Lung Cancer 2005; 50: 129-137). The principle of all CECOG consensus is such that evidence-based recommendations for state-of-the-art treatment are given upon which all participants and authors of the manuscript have to agree (Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). This is of particular importance in diseases in which treatment options depend on very particular clinical and biologic variables (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer--update 2004. Lung Cancer 2005; 50: 129-137; Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). Since the publication of the last CECOG consensus on the medical treatment of NSCLC, a series of diagnostic tools for the characterization of biomarkers for personalized therapy for NSCLC as well as therapeutic options including adjuvant treatment, targeted therapy, and maintenance treatment have emerged and strongly influenced the field. Thus, the present third consensus was generated that not only readdresses previous disease-related issues but also expands toward recent developments in the management of NSCLC. It is the aim of the present consensus to summarize minimal quality-oriented requirements for individual patients with NSCLC in its various stages based upon levels of evidence in the light of a rapidly expanding array of individual therapeutic options.

show abstract

Consensus on medical treatment of non-small-cell lung cancer—update 2004

Cited by 3 publications

References 64 publications

Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer

Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer

memo – New official Journal of CECOG

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer

Contact Info

Product

Resources

About